COMMUNIQUÉS West-GlobeNewswire

-
Invitation to investor meeting on November 8, 2018
05/11/2018 -
Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
05/11/2018 -
Capital Senior Living Corporation to Present at the Stephens NY Investment Conference on Wednesday, November 7, 2018
05/11/2018 -
Arrayit Corporation Announces Brands Expansion of Proprietary Finger Stick Allergy Testing
05/11/2018 -
Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ)
05/11/2018 -
William Demant Holding A/S: Financial calendar 2019
05/11/2018 -
Biohit Oyj B-shares Subscribed with Stock Options I 2013
05/11/2018 -
Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018
05/11/2018 -
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
05/11/2018 -
ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018
05/11/2018 -
ERYTECH tiendra un colloque avec des leaders d’opinion retransmis en direct le 7 novembre 2018
05/11/2018 -
Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes
05/11/2018 -
Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment
05/11/2018 -
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
05/11/2018 -
Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes
05/11/2018 -
Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors
05/11/2018 -
Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
05/11/2018 -
Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes
05/11/2018 -
Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
05/11/2018
Pages